|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
We wished to investigate whether the HABMs of USP17 were responsible for tumor suppression activity.
|
22662218 |
2012 |
|
Endometriosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Whole exome sequencing identifies hemizygous deletions in the UGT2B28 and USP17L2 genes in a three‑generation family with endometriosis.
|
30628680 |
2019 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Our study reveals a critical Dub3-Snail1 signalling axis in EMT and metastasis, and provides an effective therapeutic approach against breast cancer.
|
28198361 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28650472 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
|
26378038 |
2015 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28288134 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Overall, our study establishes the CDK4/6-DUB3 axis as an important regulatory mechanism of breast cancer metastasis and provides a rationale for potential therapeutic interventions in the treatment of breast cancer metastasis.
|
28067227 |
2017 |
|
Malignant neoplasm of breast
|
0.070 |
Biomarker
|
disease |
BEFREE |
Correction: DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
31068665 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
USP17 Suppresses Tumorigenesis and Tumor Growth through Deubiquitinating AEP.
|
30906206 |
2019 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Patients with USP17 positive tumors had significantly reduced recurrence-free survival than patients with USP17 negative tumors.
|
24123619 |
2013 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Correction: DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
31068665 |
2019 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Overall, our study establishes the CDK4/6-DUB3 axis as an important regulatory mechanism of breast cancer metastasis and provides a rationale for potential therapeutic interventions in the treatment of breast cancer metastasis.
|
28067227 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our study reveals a critical Dub3-Snail1 signalling axis in EMT and metastasis, and provides an effective therapeutic approach against breast cancer.
|
28198361 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28650472 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
|
28288134 |
2017 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells.
|
26378038 |
2015 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These data support the possibility that SDS3, being a substrate of USP17, may play an important role in developing a novel therapeutic means to inhibit specific HDAC activities in cancer.
|
21239494 |
2011 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our findings identify a previously unrecognized mechanism causing BRD4 upregulation and drug resistance, suggesting that DUB3 is a viable therapeutic target to overcome BET inhibitor resistance in cancer.
|
30057199 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Of importance, Dub3 interacted with Slug and Twist and prevented them from degradation, thereby promoting migration, invasion, and cancer stem cell (CSC)-like properties of breast cancer cells.
|
29088851 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These data support the possibility that SDS3, being a substrate of USP17, may play an important role in developing a novel therapeutic means to inhibit specific HDAC activities in cancer.
|
21239494 |
2011 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Of importance, Dub3 interacted with Slug and Twist and prevented them from degradation, thereby promoting migration, invasion, and cancer stem cell (CSC)-like properties of breast cancer cells.
|
29088851 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Our findings identify a previously unrecognized mechanism causing BRD4 upregulation and drug resistance, suggesting that DUB3 is a viable therapeutic target to overcome BET inhibitor resistance in cancer.
|
30057199 |
2018 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Intriguingly, Dub3 was identified as an early response gene that was upregulated after exposure to inflammatory cytokines such as IL-6, which plays a critical role in the growth and metastasis of breast cancer cells, as well as the maintenance of breast CSCs.
|
29088851 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our study reveals a critical Dub3-Snail1 signalling axis in EMT and metastasis, and provides an effective therapeutic approach against breast cancer.
|
28198361 |
2017 |
|
Neoplasm Metastasis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Overall, our study establishes the CDK4/6-DUB3 axis as an important regulatory mechanism of breast cancer metastasis and provides a rationale for potential therapeutic interventions in the treatment of breast cancer metastasis.
|
28067227 |
2017 |